<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    TG Therapeutics, Inc.

    TG Therapeutics, Inc.

    TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...

    TG Therapeutics is a biopharmaceutical company ...

    Filing Type:    PU
    Wright Medical Group N.V.

    Wright Medical Group N.V.

    Wright Medical Group N.V. is a global medical device company focused on Extremitie...

    Wright Medical Group N.V. is a global medical d...

    Filing Type:    PU
    Rian Enterprises, Inc.

    Rian Enterprises, Inc.

    Health Journal is a leader and influencer in health publishing in Virginia, USA an...

    Health Journal is a leader and influencer in he...

    Amount Raised:    $1,400.00
    Fundraising Status:    EC
    Filing Type:    CF
    Halo Cures, Inc.

    Halo Cures, Inc.

    Halo gives scientists and academics opportunities to connect with industry partner...

    Halo gives scientists and academics opportuniti...

    Filing Type:    CF
    AVROBIO, Inc.

    AVROBIO, Inc.

    AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage co...

    AVROBIO, Inc., a leader in lentiviral-based gen...

    Filing Type:    PU
    CytoDyn Inc.

    CytoDyn Inc.

    CytoDyn is a publicly traded late stage biotechnology company developing innovativ...

    CytoDyn is a publicly traded late stage biotech...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Cytosorbents Corporation

    Cytosorbents Corporation

    CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...

    CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...

    Filing Type:    PU
    Aptose Biosciences, Inc.

    Aptose Biosciences, Inc.

    Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...

    Aptose Biosciences is a clinical-stage biotechn...

    Filing Type:    PU
    NGM Biopharmaceuticals, Inc.

    NGM Biopharmaceuticals, Inc.

    We are a clinical stage biopharmaceutical company focused on harnessing powerful b...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    Exicure, Inc.

    Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...

    Exicure, Inc. is a clinical stage biotechnology...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.